Cost-Effectiveness Analysis of Linagliptin in Japan Based on Results from the Asian Subpopulation in the CARMELINA(®) Trial

INTRODUCTION: We evaluated the cost-effectiveness of linagliptin in Japan by estimating the lifetime outcome based on clinical event rates from the Asian subpopulation of the CARMELINA trial. In CARMELINA, linagliptin added to standard of care (SoC) versus SoC demonstrated noninferiority with regard...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Diabetes Ther
Main Authors: Watada, Hirotaka, Sakamaki, Hiroyuki, Yabe, Daisuke, Yamamoto, Fumiko, Murata, Tatsunori, Hanada, Keigo, Hirase, Tetsuaki, Okamura, Tomoo
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Healthcare 2020
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7376765/
https://ncbi.nlm.nih.gov/pubmed/32557283
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13300-020-00852-8
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados